MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Cogent Biosciences Inc

Închisă

16.28 -0.18

Rezumat

Modificarea prețului

24h

Curent

Minim

16.26

Maxim

16.37

Indicatori cheie

By Trading Economics

Venit

-1.5M

-74M

Marjă de profit

-1,582.642

Angajați

205

EBITDA

1.7M

-72M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+27.03% upside

Dividende

By Dow Jones

Următoarele câștiguri

10 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

583M

2.3B

Deschiderea anterioară

16.46

Închiderea anterioară

16.28

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Cogent Biosciences Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

19 oct. 2025, 20:00 UTC

Achiziții, Fuziuni, Preluări

Infratil Agrees to NZ$437.7 Million Deal to Raise Contact Energy Stake

19 oct. 2025, 23:44 UTC

Market Talk

Gold Edges Lower Amid Signs of U.S.-China Trade Tensions Easing -- Market Talk

19 oct. 2025, 23:37 UTC

Market Talk

New Zealand's Core CPI Keeps Rate Cut Hopes Alive -- Market Talk

19 oct. 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street Gains -- Market Talk

19 oct. 2025, 23:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 oct. 2025, 23:09 UTC

Market Talk

Could Rio Tinto, BHP Ally to Defend Iron-Ore Pricing Power? -- Market Talk

19 oct. 2025, 22:41 UTC

Achiziții, Fuziuni, Preluări

Luxury Fashion House Kering Confirms Beauty Deal With L'Oréal -- Barrons.com

19 oct. 2025, 22:30 UTC

Câștiguri

Stock Futures Rise Ahead of Major Week of Earnings -- Barrons.com

19 oct. 2025, 22:18 UTC

Market Talk

Gold at $5,000 on Cards as Investors Get Comfortable -- Market Talk

19 oct. 2025, 21:50 UTC

Market Talk

Infratil's Contact Stake Buy May Require Bigger Asset Sales -- Market Talk

19 oct. 2025, 21:15 UTC

Market Talk

Investors Need to Change Narrative Toward Scales -- Market Talk

19 oct. 2025, 19:34 UTC

Achiziții, Fuziuni, Preluări

Infratil's Contact Shareholding to Rise to 14.3% When Deal Completes

19 oct. 2025, 19:34 UTC

Achiziții, Fuziuni, Preluări

Infratil to Issue New Shares Worth NZ$218.8 Million to TECT at NZ$12.43 Each

19 oct. 2025, 19:33 UTC

Achiziții, Fuziuni, Preluări

Infratil Part-Funding Purchase of Contact Energy Stake With NZ$218.8 Million of Existing Debt

19 oct. 2025, 19:32 UTC

Achiziții, Fuziuni, Preluări

Infratil Acquiring Additional Contact Energy Stake for NZ$8.95/Share

19 oct. 2025, 19:32 UTC

Achiziții, Fuziuni, Preluări

Infratil Acquiring Contact Energy Stake for NZ$437.7 Million

19 oct. 2025, 19:31 UTC

Achiziții, Fuziuni, Preluări

Infratil Acquiring TECT Holdings's Shareholding in Contact Energy

19 oct. 2025, 19:31 UTC

Achiziții, Fuziuni, Preluări

Infratil to Acquire Additional 4.92% Stake in Contact Energy

19 oct. 2025, 16:29 UTC

Câștiguri

Elon Musk Pay Drama Heats Up Ahead of Tesla Earnings -- Barrons.com

19 oct. 2025, 11:14 UTC

Câștiguri

Zijin Mining 3Q Oper Income CNY86.49B; up 8.1% on Year>2899.HK

19 oct. 2025, 11:14 UTC

Câștiguri

Zijin Mining: Higher Sales of Gold, Copper Supported Results >2899.HK

19 oct. 2025, 11:14 UTC

Câștiguri

Zijin Mining 3Q Net CNY14.57B; up 57.1% on Year>2899.HK

18 oct. 2025, 13:30 UTC

Achiziții, Fuziuni, Preluări

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 oct. 2025, 13:30 UTC

Achiziții, Fuziuni, Preluări

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 oct. 2025, 13:30 UTC

Achiziții, Fuziuni, Preluări

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 oct. 2025, 13:30 UTC

Achiziții, Fuziuni, Preluări

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 oct. 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

17 oct. 2025, 23:25 UTC

Achiziții, Fuziuni, Preluări

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 oct. 2025, 22:15 UTC

Market Talk

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 oct. 2025, 21:15 UTC

Market Talk

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

Comparație

Modificare preț

Cogent Biosciences Inc Așteptări

Obiectiv de preț

By TipRanks

27.03% sus

Prognoză pe 12 luni

Medie 20.82 USD  27.03%

Maxim 30 USD

Minim 11 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCogent Biosciences Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

12 ratings

9

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

4.88 / 5.87Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

Strong Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
help-icon Live chat